Glaukos

Glaukos EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Glaukos (GKOS) as of Oct 28, 2026 is -86.73 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -117.48 M USD — a change of -26.17% (higher).

EBITDA

-86.73 MUSD

YoY

-26.17%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Glaukos is 2025 -86.73 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Glaukos was 2024 -117.48 M USD. It decreases by -26.17% higher compared to the previous year.

The Glaukos EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-13.00 M USD
Jan 1, 2019
-48.19 M USD
Jan 1, 2020
-115.38 M USD
Jan 1, 2021
-31.98 M USD
Jan 1, 2022
-84.68 M USD
Jan 1, 2023
-124.04 M USD
Jan 1, 2024
-117.48 M USD
Jan 1, 2025
-86.73 M USD
The Glaukos EBITDA history
YEAREBITDAYoY
-86.73 MUSD-26.17%
-117.48 MUSD-5.29%
-124.04 MUSD+46.47%
-84.68 MUSD+164.78%
-31.98 MUSD-72.28%
-115.38 MUSD+139.41%
-48.19 MUSD+270.65%
-13.00 MUSD+470.01%
-2.28 MUSD-153.78%
4.24 MUSD-141.19%
-10.30 MUSD-21.83%
-13.17 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Glaukos Stock analysis

What does Glaukos do? Glaukos Corp is a medical technology company specializing in developing devices and therapies for treating eye diseases. It was founded in 1998 by employees of the ophthalmology center at the University of California San Francisco. The company focuses on utilizing new technologies and therapies to improve the vision quality of patients. They have developed innovative products for diagnosing and treating various eye conditions, including glaucoma. Their core business involves manufacturing and distributing medical devices for glaucoma treatment, such as the iStent implant. They have also partnered with other institutions to advance research and development in the field of ophthalmology. In 2018, Glaukos Corp acquired the German manufacturer Markt II Medical, expanding their product offerings for a wider range of eye diseases. In summary, Glaukos Corp is an innovative medical technology company that aims to enhance patients' vision quality while minimizing the risks of eye surgery. Glaukos is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Glaukos stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Glaukos is -86.73 M USD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Glaukos changed from -117.48 M USD to -86.73 M USD, representing a -26.17% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Glaukos since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Glaukos historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Glaukos

All Key Metrics — Glaukos